International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 56-60 , April 2010

Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models

  • S.K. Mastan

      Affiliations

    • Research Scholar, Jawaharlal Nehru Technological University, Hyderabad 500 072, Andhra Pradesh, India
    • Corresponding Author InformationCorresponding author. Tel.: +91 891 2733737; fax: +91 891 2525611.
    • ,
  • K. Eswar Kumar

      Affiliations

    • Pharmacology Division, AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530 003, Andhra Pradesh, India

Received 20 July 2009 ,Accepted 5 October 2009.

References 

  1. Satyanarayana S, Kumar EK. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol Cell Biochem. 2006;291:101–105
  2. King H, Aubert RE, Heiman WH. Prevalence: numerical estimates and projections. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–1431
  3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The third national health and nutrition examination survey 1988–1994. Diabetes Care. 1998;21:518–524
  4. Hruz PW. Molecular mechanisms for altered glucose homeostasis in HIV infection. Am J Infect Dis. 2006;2:87–192
  5. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467–1475
  6. Haas DW, Zala C, Schrader S, Piliero P, Jaeger H, Nunes D, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS. 2003;17:339–349
  7. Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism. 2003;52:29–34
  8. Brien RC, Luo M, Balazs N, Mercuri J. In vitro and in vivo antioxidant properties of gliclazide. J Diabetes Complicat. 2000;14:201–206
  9. Harrower AD. Efficacy of gliclazide in comparison with other sulphonylureas in the treatment of NIDDM. Diabetes Res Clin Pract. 1991;14:S65–S67
  10. Mastan SK, Chaitanya G, Reddy KR, Kumar KE. An appraisal to the special sulphonylurea: gliclazide. Pharmacologyonline. 2009;1:254–269
  11. Busti AJ, Hall RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:1732–1747
  12. Satyanarayana S, Eswar Kumar K, Rajasekhar J, Thomas L, Rajanna S, Rajanna B. Influence of aqueous extract of fenugreek-seed powder on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Therapy. 2007;4:457–463
  13. In:  Lawrence DR,  Bacharach AL editor. Evaluation of drug activities: pharmacometrics. vol. I:New York: Academic Press; 1964;
  14. Shibata N, Gao W, Okamoto H, Kishida T, Iwasaki K, Yashikawa Y, et al. Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model. J Pharm Sci. 2002;91:680–689
  15. Heikkila RE. The prevention of alloxan-induced diabetes in mice by dimethyl sulfoxide. Eur J Pharmacol. 1977;44:191–193
  16. Riley V. Adaptation of orbital bleeding technique to rapid serial blood studies. Proc Soc Exp Biol Med. 1960;104:751–754
  17. Trinder P. Determination of blood glucose using an oxidaase-peroxidase system with a non carcinogenic chemogen. J Clin Pathol. 1969;22:158–161
  18. Kumar KE, Ramesh A, Yadav RS, Satyanarayana S. Determination of gliclazide in rabbit serum by RP-HPLC. Acta Ciencia Indica Chem. 2007;33:273–278
  19. Davis TME, Daly F, Walsh JP, Ilett KF, P Beilby J, Barrett PHR, et al. Pharmacokinetics and pharmacodynamics of gliclazide in caucasians and Australian aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49:223–230
  20. Wang S, Mulvey R, Elosua C, Flint OP, Parker RA. Association of HIV-protease inhibitors with insulin resistance is related to potency of inhibition of GLUT4 and GLUT1 activity in adipocytes and myocytes. Antiviral Ther. 2003;8:L36
  21. Noor MA, Parker RA, O’Mara E, Grasela DM, Fiedorek AFT, Haas DW, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137–2144
  22. Campbell DB, Lavielle R, Nathan C. The mode of action on clinical pharmacology of gliclazide a review. Diabetes Res Clin Pract. 1991;14:S21–S36
  23. Reyataz FDA label information, <http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021567s017lbl.pdf>; 2009 [accessed 20.07.09].
  24. Oida T, Yoshida K, Kagemoto A, Sekine Y, Higashijima T. The metabolism of gliclazide in man. Xenobiotica. 1985;15:87–96

PII: S1877-5934(09)00053-8

doi: 10.1016/j.ijdm.2009.10.001

International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 56-60 , April 2010

Article Tools

* Image Usage & Resolution